ACIPHEX / PARIET Expanded Manufacturing Facility Completed at Misato Plant
Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced today the company celebrated the dedication of a new formulation facility, N1 Building, at the Misato Plant in Saitama Prefecture, on January 18.
The N1 Building will enable the company to expand the production capacity for the proton pump inhibitor, ACIPHEX / PARIET (rabeprazole sodium), meeting increasing worldwide demand while reducing the production cost*1. In addition, the facility has incorporated packaging operations previously performed in the older building and was also designed to accommodate regulatory agencies' guidelines for Good Manufacturing Practices (GMPs), which have become increasingly stringent for all pharmaceutical manufacturers.
The N1 Building is designed for maximum operational safety, protecting workers from any potential chemical hazard, as well as taking resource conservation into consideration by introducing a variety of cutting-edge energy-efficient equipment*2.
PARIET was first launched in Japan in 1977, and it was launched under the tradename ACIPHEX in the United States in 1999. Currently the product has been launched in approximately 72 countries worldwide.
With the completion of the new N1 Building, for ACIPHEX / PARIET production expansion, Eisai's Misato Plant will become one of the company's flagship manufacturing facilities.
Eisai has a long history of introducing innovative new treatments in gastroenterology and will continue to contribute to the treatment of patients with acid related diseases.
Corporate Communications Department
Eisai Co., Ltd.
Phone 03-3817-5120 (Tokyo)
[ The outline of N1 Building and Misato Plant are attached below for reference. ]
[ N1 Building Outline ]
[ N1 Building Floor Area and Functions ]
Note : The building is a five-storied structure but incorporates the second and fourth floor as mezzanine floors.
[ Misato Plant Outline ]
N1 Building Photograph